Introduction: Geographic transferability of model-based cost-effectiveness results may facilitate and shorten the reimbursement process of new pharmaceuticals. This study provides a real world example of transferring a cost-effectiveness study of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer from the United Kingdom to The Netherlands. Methods: Three successive steps were taken. Step 1: Collect available information with regard to the original model, and assess transferability using existing checklists. Step 2: Adapt transferability-limiting factors. Step 3: Obtain a country-specific estimate of cost-effectiveness. Results: The structure of the UK model was transferable, although some of the model inputs needed adaptation. From a health-care perspective, the Dutch estimate amounted to €5828/quality-adjusted life-year gained. From a societal perspective, the incremental cost-effectiveness ratio was dominant. Conclusion: Transferability of a model-based UK-study in three steps proved to be an efficient method to provide an early indication of the cost-effectiveness of trastuzumab and has led to the provisional reimbursement of the treatment.

Additional Metadata
Keywords HER2-positive breast cancer, Netherlands, United Kingdom, article, breast cancer, cost effectiveness analysis, economic evaluation, epidermal growth factor receptor 2, health care, human, medical information, model-based economic evaluation, outcome assessment, priority journal, quality of life, transferability, trastuzumab
Persistent URL dx.doi.org/10.1111/j.1524-4733.2009.00683.x, hdl.handle.net/1765/20729
Citation
Essers, B.A.B., Seferina, S.C., Tjan-Heijnen, V.C.G., Severens, J.L., Novák, A., Pompen, M., … Joore, M.A.. (2010). Transferability of model-based economic evaluations: The case of trastuzumab for the adjuvant treatment of her2-positive early breast cancer in the netherlands. Value in Health, 13(4), 375–380. doi:10.1111/j.1524-4733.2009.00683.x